Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can cause rheumatic immune-related adverse events (irAEs), ranging from inflammatory arthritis and polymyalgia rheumatica-like disease to life-threatening myositis overlap syndromes, vasculitis, and giant cell arteritis-like disease. Their heterogeneous clinical presentations, potential chronicity, and implications for anticancer treatment complicate clinical decision-making. This review summarizes current evidence on the recognition, initial risk stratification, major clinical phenotypes, and risk-adapted management of ICI-associated rheumatic irAEs. We discuss glucocorticoid use and tapering, glucocorticoid-sparing therapy, and individualized decisions regarding ICI continuation, interruption, discontinuation, and rechallenge. Long-term follow-up should integrate inflammatory disease activity, physical function, treatment-related toxicity, ICI treatment continuity, and oncologic outcomes. Multidisciplinary management is essential to balance adequate control of inflammation with preservation of anticancer benefit. Future studies should establish standardized diagnostic criteria, phenotype-specific treatment strategies, prospective risk-prediction models, and validated long-term outcome measures.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: